We've all seen those huge spikes in SP and they're usually biotechs who have had favourable trial results or FDA approval. So I've taken time to look into various companies with potential milestone events this month.
The single stockpick I have come up with is Vanda Pharma (VNDA) which is a small-cap biotech with a growing commercial foundation.
Already has sales momentum with Fanept and recent approval of Nereus trapitant for motion sickness, which triggered strong stock moves late last year.
Target decision date for FDA is date is Feb 21st for Bysantii which is a new antipsychotic for bipolar I disorder and schizophrenia
Approval of Bysanti expand VNDA’s commercial portfolio beyond Fanapt and NEREUS into a larger psychiatric market potentially boosting future revenue and investor confidence.
Well funded with $263.8 million to help any near term spending without any risk of dilution.
Overall VNDAs Outlook includes multiple catalysts in 2026 .
worth a look.